Existing investors Prism VentureWorks, Charter Life Sciences, Ascent Biomedical and Aperture Venture Partners also renewed their commitment to Xlumena through the round, which the company said would be used to extend its global commercialisation efforts.
Xlumena makes advanced endoscopy devices, which are used to look inside the human body.
Earlier this year Silicon Valley-based venture capital firm Canaan Partners led a $9m Series B funding round for Minimally Invasive Devices (MID) to help the medical products maker expand its manufacturing and sales activities.
The round was also backed by Xlumena investor Charter Life Sciences, which was already a backer of the business.
MID’s core product is the FloShield vision system, which helps keep video systems used in laparoscopic surgeries clean by using an air curtain to use as a protective barrier over the lens.
Copyright © 2013 AltAssets